Because Zepbound is FDA-approved, the SURMOUNT-1 trial result (22.5% mean weight loss with 15mg tirzepatide over 72 weeks) applies to it unlike compounded tirzepatide, which is not FDA-approved and has not been evaluated at that trial scale
While these findings were reassuring, there were other findings of note
Wellbutrin (bupropion) alone does have modest appetite-suppressing effects and has been studied for weight loss off-label
Retatrutide Retatrutide is a triple agonist (GIP/GLP-1/glucagon receptor) currently in late-stage clinical trials that has shown remarkable weight loss results of up to 24% in Phase 2 studies
Combining drops with other medications Some people take GLP-1 drops alongside other medications that also benefit from empty stomach administration
Healthcare providers can assess whether symptoms represent medication adverse effects, complications of treatment, or unrelated medical conditions requiring specific intervention